BR112020004226A2 - compostos e composições para inibição de ire1 - Google Patents

compostos e composições para inibição de ire1 Download PDF

Info

Publication number
BR112020004226A2
BR112020004226A2 BR112020004226-9A BR112020004226A BR112020004226A2 BR 112020004226 A2 BR112020004226 A2 BR 112020004226A2 BR 112020004226 A BR112020004226 A BR 112020004226A BR 112020004226 A2 BR112020004226 A2 BR 112020004226A2
Authority
BR
Brazil
Prior art keywords
amino
pyrazin
imidazo
naphthalen
cyclohex
Prior art date
Application number
BR112020004226-9A
Other languages
English (en)
Portuguese (pt)
Inventor
Richard M. Keenan
Scott A. Oakes
Bradley J. Backes
Dustin J. Maly
Charles Reynolds
Ben Whittaker
Jamie Knight
Jon Sutton
George Hynd
Feroz R. Papa
Original Assignee
Optikira Llc
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Optikira Llc, The Regents Of The University Of California filed Critical Optikira Llc
Publication of BR112020004226A2 publication Critical patent/BR112020004226A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
BR112020004226-9A 2017-09-01 2018-08-31 compostos e composições para inibição de ire1 BR112020004226A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762553320P 2017-09-01 2017-09-01
US62/553,320 2017-09-01
PCT/US2018/049081 WO2019046711A2 (en) 2017-09-01 2018-08-31 COMPOUNDS AND COMPOSITIONS FOR INHIBITING IRE1

Publications (1)

Publication Number Publication Date
BR112020004226A2 true BR112020004226A2 (pt) 2020-11-17

Family

ID=65526075

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020004226-9A BR112020004226A2 (pt) 2017-09-01 2018-08-31 compostos e composições para inibição de ire1

Country Status (13)

Country Link
US (1) US11649237B2 (enExample)
EP (1) EP3675858B1 (enExample)
JP (1) JP2020532589A (enExample)
KR (1) KR20200066301A (enExample)
CN (1) CN111526877B (enExample)
AU (1) AU2018326721B2 (enExample)
BR (1) BR112020004226A2 (enExample)
CA (1) CA3074139A1 (enExample)
IL (1) IL272845B2 (enExample)
MX (1) MX2020002322A (enExample)
SG (1) SG11202001609RA (enExample)
WO (1) WO2019046711A2 (enExample)
ZA (1) ZA202001320B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7444458B2 (ja) * 2018-09-21 2024-03-06 学校法人福岡大学 プリオン病治療薬
US20220194945A1 (en) * 2019-02-27 2022-06-23 Optikira, LLC Imidazolopyridine Compounds For IRE1 Inhibition
EP3930718A4 (en) * 2019-02-27 2022-10-05 Optikira LLC Pyrazolopyridine compounds for ire1 inhibition
US20230331719A1 (en) * 2020-08-07 2023-10-19 Optikira, LLC Pyrazolopyridine Compounds and Methods of Inhibiting IRE1 Using Same
KR20230118855A (ko) * 2020-11-13 2023-08-14 더 리전츠 오브 더 유니버시티 오브 캘리포니아 IRE1α 억제제 및 이의 용도
EP4460492A1 (en) * 2022-01-07 2024-11-13 (INSERM) Institut National de la Santé et de la Recherche Médicale Compounds containing a hydroxyphenyl moiety and their use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR057960A1 (es) * 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
EP2283020B8 (en) * 2008-05-19 2012-12-12 OSI Pharmaceuticals, LLC Substituted imidazopyr-and imidazotri-azines
WO2011047384A2 (en) 2009-10-16 2011-04-21 The Regents Of The University Of California Methods of inhibiting ire1
MX2012011504A (es) 2010-04-05 2013-01-18 Mannkind Corp Inhibidores de enzima 1 dependiente de inositol (ire-1 alfa).
EP2548877A1 (en) 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
RU2015115631A (ru) * 2012-09-26 2016-11-20 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Модулирование ire1
WO2016004254A1 (en) * 2014-07-01 2016-01-07 The Regents Of The University Of California Combined modulation of ire1
US20170252350A1 (en) 2016-03-03 2017-09-07 Cornell University Small molecule ire1-alpha inhibitors
EP3548476A4 (en) 2016-12-02 2020-05-20 Quentis Therapeutics, Inc. SMALL MOLECULAR IRE1 INHIBITORS

Also Published As

Publication number Publication date
US20200354367A1 (en) 2020-11-12
KR20200066301A (ko) 2020-06-09
EP3675858A2 (en) 2020-07-08
CN111526877B (zh) 2023-08-25
CA3074139A1 (en) 2019-03-07
SG11202001609RA (en) 2020-03-30
US11649237B2 (en) 2023-05-16
AU2018326721A1 (en) 2020-03-12
EP3675858B1 (en) 2023-04-26
CN111526877A (zh) 2020-08-11
WO2019046711A3 (en) 2020-04-02
IL272845B2 (en) 2023-12-01
RU2020112425A (ru) 2021-10-04
IL272845A (en) 2020-04-30
ZA202001320B (en) 2023-10-25
RU2020112425A3 (enExample) 2022-03-31
MX2020002322A (es) 2020-10-05
EP3675858A4 (en) 2021-03-17
AU2018326721B2 (en) 2022-12-01
JP2020532589A (ja) 2020-11-12
WO2019046711A2 (en) 2019-03-07
IL272845B1 (en) 2023-08-01

Similar Documents

Publication Publication Date Title
BR112020004226A2 (pt) compostos e composições para inibição de ire1
JP5966014B2 (ja) 新規トリフルオロメチル−オキサジアゾール誘導体および疾患の処置におけるその使用
US12187712B2 (en) Cardiac sarcomere inhibitors
TWI280127B (en) Remedies for neurodegenerative diseases
CN117924208A (zh) 作为心肌节抑制剂的二氢苯并呋喃和茚类似物
CN110603254A (zh) 被取代的吡唑化合物以及使用其治疗过度增生性疾病的方法
BRPI0814958B1 (pt) Compostos de indol, e, composição
WO2019101086A1 (zh) 卤代烯丙基胺类ssao/vap-1抑制剂及其应用
TW200307535A (en) Therapeutic agent for cancer
TW200843770A (en) RHO kinase inhibitors
JP2020503268A (ja) 選択的hdac1、2阻害剤としてのピペラジン誘導体
CN109843879B (zh) 作为dyrk1抑制剂的苯并噻唑衍生物
JP2019509272A (ja) 脊髄性筋萎縮症の治療のための併用療法
EA037264B1 (ru) Гетероциклическое сульфонамидное производное и содержащее его лекарственное средство
TW202340166A (zh) 多環化合物
CN102807575A (zh) 3-芳基-5-噻吩基-5H-噻唑并[3,2-a]嘧啶类衍生物及其应用
CN102796121B (zh) 3-芳基-7H-噻唑并[3,2-b]-1,2,4-三嗪-7-酮类衍生物及其应用
JP2019516677A (ja) アクアポリンを調節するための化合物
RU2795572C2 (ru) Соединения и композиции для ингибирования ire1
KR20170117024A (ko) 생체 아민 수송 조절인자로서 신규한 퀴나졸린
JP2022521784A (ja) Ire1阻害のためのピラゾロピリジン化合物
CN110724076B (zh) 对芳基二甲酰胺类化合物、包含其的药物组合物、其制备方法及其用途
WO2024040190A1 (en) Indane and coumaran derivatives as fast skeletal muscle myosin inhibitors
KR20240046553A (ko) Sting 길항제로서의 소분자 우레아 유도체
KR20250037566A (ko) Irak3 결합제로서의 치환된 이미다조피라진 화합물

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]